Skip to content

The digital intervention of a glycated albumin (GA) self-monitoring system for patients with type 2 diabetes

The digital intervention of a glycated albumin (GA) self-monitoring system for patients with type 2 diabetes: a randomized, open-label, non-intervention group controlled, single-center clinical study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs042220048
Enrollment
100
Registered
2022-08-03
Start date
2022-08-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus type 2 diabetes mellitus

Interventions

Study subjects assigned to the intervention group will have GA measured once a week and will record daily behavioral assessments of treatment goals on the application. Patients assigned to the non-int
digital intervention, glycated albumin, type 2 diabetes mellitus, clinical study, self-monitoring

Sponsors

Jinnouchi Hideaki
Lead Sponsor
Provigate, Inc.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who meet the diagnostic criteria for type 2 diabetes mellitus of the Japan Diabetes Society (2) Patients whose HbA1c measured on the date of consent is 7.0 or higher and 9.0 or lower (3) Patients who understand the contents of the consent document describing the purpose and methods of the study and agree in writing to participate in the study. (4) Patients who are 20 years of age or older at the time consent is obtained (5) Patients who have a smartphone that can use the application

Exclusion criteria

Exclusion criteria: (1) Patients on insulin therapy (2) Patients on GLP-1 injection therapy (3) Patients under inpatient care (4) Patients with confirmed or suspected type 1 diabetes (5) Patients whose HbA1c level has changed 0.8% or more in the 2 visits prior to obtaining consent and whose symptoms have not stabilized (6) Patients who have undergone a change in drug therapy in the 2 months prior to obtaining consent and whose therapeutic response has not stabilized (7) Patients who have difficulty or prohibit from following diet or exercise therapy due to other medical conditions (8) Severely obese patients (BMI > 35) (9) Patients with diseases or conditions known to cause a discrepancy between GA and blood glucose levels (hyperthyroidism, nephrosis, ascites (peritoneal dialysis), steroid diabetes, high BMI, hypothyroidism, liver cirrhosis, hyponutrition) (10) Patients with concomitant diseases that affect HbA1c test values (abnormal hemoglobinemia, hemolytic anemia, bleeding disorders, renal failure, patients receiving erythropoietin) (11) Patients with inadequate responses to required questionnaires (12) Patients with difficulty in self finger-prick blood sampling

Design outcomes

Primary

MeasureTime frame
1) Glycoalbumin (GA) 2) Energy intake and nutrient composition 3) Physical activity level

Secondary

MeasureTime frame
1) HbA1c 2) Bodyweight 3) BMI 4) Abdominal circumference 5) Self-efficacy scale for diabetes self-care 6) Exercise self-efficacy scale for diabetes self-care

Contacts

Public ContactAkira Yoshida

Jinnouchi Hospital

ct@jinnouchi.or.jp+81-96-363-0011

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026